Back to top
more

QIAGEN (QGEN)

(Delayed Data from NYSE)

$43.23 USD

43.23
852,176

-0.82 (-1.86%)

Updated Nov 12, 2024 04:00 PM ET

After-Market: $43.26 +0.03 (0.07%) 6:48 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value C Growth A Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 29% (73 out of 249)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Don't Overlook Qiagen (QGEN) International Revenue Trends While Assessing the Stock

by Zacks Equity Research

Evaluate Qiagen's (QGEN) reliance on international revenue to better understand the company's financial stability, growth prospects and potential stock price performance.

Why Qiagen (QGEN) is a Top Value Stock for the Long-Term

by Zacks Equity Research

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Moumi Mondal headshot

Hologic Post Q4 Earnings Miss: Time to Buy, Hold or Sell the Stock?

by Moumi Mondal

Despite the recent earnings miss, Hologic's portfolio strength and capital allocation strategy can be appealing to investors.

QIAGEN Stock Flat Post Q3 Earnings & Revenue Beat, 2024 EPS View Up

by Zacks Equity Research

QGEN delivers another solid performance in the third quarter of 2024, with both the top and bottom lines surpassing estimates.

Compared to Estimates, Qiagen (QGEN) Q3 Earnings: A Look at Key Metrics

by Zacks Equity Research

While the top- and bottom-line numbers for Qiagen (QGEN) give a sense of how the business performed in the quarter ended September 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Qiagen (QGEN) Q3 Earnings and Revenues Top Estimates

by Zacks Equity Research

Qiagen (QGEN) delivered earnings and revenue surprises of 5.56% and 2.31%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

QGEN Stock Set to Gain From FDA's Clearance of QIAstat-Dx Mini Panel

by Zacks Equity Research

QIAGEN wins FDA clearance for the QIAstat-Dx mini panel to improve precision in outpatient respiratory treatment.

Qiagen (QGEN) Q3 Earnings Preview: What You Should Know Beyond the Headline Estimates

by Zacks Equity Research

Beyond analysts' top -and-bottom-line estimates for Qiagen (QGEN), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended September 2024.

EyePoint Pharmaceuticals (EYPT) Soars 27.6%: Is Further Upside Left in the Stock?

by Zacks Equity Research

EyePoint Pharmaceuticals (EYPT) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Moumi Mondal headshot

Illumina's Q3 Earnings Coming Up: Time to Buy, Sell or Hold the Stock?

by Moumi Mondal

In the third quarter of 2024, ILMN is likely to have benefited from the significant step-up in consumables with growing customer activity on NovaSeq X.

Moumi Mondal headshot

Should You Buy, Sell or Hold HOLX Stock Ahead of Q4 Earnings?

by Moumi Mondal

Hologic's upcoming fourth-quarter fiscal 2024 financial report is expected to reflect strength in core franchises.

Moumi Mondal headshot

ILMN Stock Trading Near 52-Week High: Should You Buy, Sell or Hold?

by Moumi Mondal

Reaching a new one-year high, Illumina remains in investors' sight owing to its strong strategic execution and positive growth outlook.

Are You a Value Investor? This 1 Stock Could Be the Perfect Pick

by Zacks Equity Research

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

QIAGEN's TB Testing Business Gets New Exposure at Global Summit

by Zacks Equity Research

QGEN distributes over 125 million QuantiFERON-TB tests across more than 130 countries worldwide, significantly contributing to national TB control strategies.

OPK Gets Additional BARDA Funding to Develop Multispecific Antibodies

by Zacks Equity Research

OPKO Health's receipt of the additional funding from BARDA is expected to explore the MSTAR platform to prepare for outbreaks and respond rapidly to emerging viral threats.

Moumi Mondal headshot

Should You Bet on HOLX Stock This Breast Cancer Awareness Month?

by Moumi Mondal

Hologic has kicked off the annual breast cancer awareness month with a new campaign. But how well is the stock doing now?

Reasons to Retain QIAGEN Stock in Your Portfolio for Now

by Zacks Equity Research

Investors feel optimistic about QGEN's strong growth prospects in the NGS platforms. Yet, an unfavorable currency impact on the company's operations is cornering.

QIAGEN Launches QIAcuityDx Digital PCR System: Stock to Gain?

by Zacks Equity Research

QGEN expands its digital PCR portfolio with the newly launched QIAcuityDx Digital PCR System. The system will be used for clinical testing in oncology across North America and Europe.

QGEN Stock to Gain From New IVDR Win for QIAstat-Dx Systems and Panels

by Zacks Equity Research

QIAGEN receives European IVDR certification for QIAstat-Dx syndromic testing instruments and assays.

QIAGEN Stock Likely to Gain From PreAnalytiX's Newly Launched PAXgene

by Zacks Equity Research

PreAnalytiX, a joint venture of QGEN and BD, introduces the PAXgene Urine Liquid Biopsy Set. QGEN will commercialize the latest set.

QGEN Stock Might Rise on Partnership With Bode for GEDmatch PRO

by Zacks Equity Research

QIAGEN announces exclusive global commercial partnership with Bode Technology. Per the agreement, Bode will manage all commercial transactions for QIAGEN's GEDmatch PRO globally.

Why This 1 Value Stock Could Be a Great Addition to Your Portfolio

by Zacks Equity Research

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

QGEN Stock Likely to Gain From Newly Launched Assays for QIAcuity

by Zacks Equity Research

QIAGEN launches 100 new assays for QIAcuity. The newly launched assays are now available through the company???s GeneGlobe platform.

QGEN Stock Likely to Gain From Innovation Amid Competition

by Zacks Equity Research

To support internal growth, QIAGEN invests heavily in research and development for the menu expansion of its key platforms.

Can QGEN Stock Gain From the Expanded Bio-Manguinhos/Fiocruz Alliance?

by Zacks Equity Research

QIAGEN and Bio-Manguinhos/Fiocruz team up to enhance malaria and dengue detection in Brazil's national screening programs.